Oxali(IV)Fluors: fluorescence responsive oxaliplatin(IV) complexes identify a hypoxia-dependent reduction in cancer cells
Platinum(IV) anticancer agents have demonstrated the potential to overcome the limitations associated with the widely used Pt(II) chemotherapeutics, cisplatin, carboplatin, and oxaliplatin. In order to identify therapeutic scenarios where this type of chemotherapy can be applied, an improved underst...
Main Authors: | Boulet, M, Bolland, H, Hammond, E, Sedgwick, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Chemical Society
2023
|
Similar Items
-
Fluorogenic platinum(iv) complexes as potential predictors for the design of hypoxia-activated platinum(iv) prodrugs
by: Marsh, J, et al.
Published: (2024) -
Network Pharmacology and Experimental Evidence Identify the Mechanism of Astragaloside IV in Oxaliplatin Neurotoxicity
by: Xu J, et al.
Published: (2021-01-01) -
A fluorescent probe strategy for the detection and discrimination of hydrogen peroxide and peroxynitrite in cells
by: Bolland, HR, et al.
Published: (2022) -
Influence of the Number of Axial Bexarotene Ligands on the Cytotoxicity of Pt(IV) Analogs of Oxaliplatin
by: Yulia N. Nosova, et al.
Published: (2017-01-01) -
A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
by: Philipp Fronik, et al.
Published: (2022-04-01)